Safety and effectiveness of Envafolimab in cancer patients
Treatments studied
Part of Cancer clinical trials.
This study reviews the real-world safety and effectiveness of a cancer treatment called Envafolimab in patients who received it through a patient access program. Researchers will analyze your medical records to understand how well the treatment worked and what side effects patients experienced.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with cancer (solid tumor or other approved condition) and received at least one dose of Envafolimab between June 2025 and December 2026
- You had at least one imaging or clinical evaluation within 8 weeks before starting Envafolimab and at least one evaluation after starting treatment
- You have been followed for at least 6 months since your first Envafolimab dose (or your cancer progressed or you passed away during this time)
- Your medical records contain sufficient information about your cancer diagnosis, treatment dates, and how your disease responded to treatment
- You consent to having your de-identified data used for this research study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This Phase 2 study tests whether envafolimab (an immune therapy) added to standard chemo and chest radiation can improve outcomes for people with limited-stage small cell lung cancer. It’s for patients who have not had prior cancer treatment beyond an initial 2-cycle chemo start and who meet blood, organ, and imaging requirements.
This trial studies envafolimab, an anti-cancer medicine that helps the immune system fight cancer, in people with gallbladder or bile duct cancer that is advanced or has spread. It aims to see how well the treatment works and what side effects people experience.
This Phase 2 trial tests whether adding envafolimab (an immunotherapy medicine) to standard chemo and radiation improves outcomes for locally advanced cervical cancer. It may help your immune system better attack the cancer while you receive treatment aimed at cure or long-term control.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.